RHJA
PGNX

Rice Hall James & Associates’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Rice Hall James & Associates’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,776,490
Closed -$8.98M – 289
2019
Q3 		$8.98M Sell
1,776,490
-466,013
-21% -$2.32M 0.32% 105
2019
Q2 		$13.8M Sell
2,242,503
-50,676
-2% -$244K 0.46% 87
2019
Q1 		$10.6M Buy
2,293,179
+369,680
+19% +$1.67M 0.34% 101
2018
Q4 		$8.08M Buy
1,923,499
+578,239
+43% +$2.94M 0.29% 106
2018
Q3 		$8.44M Sell
1,345,260
-44,580
-3% -$342K 0.3% 100
2018
Q2 		$11.2M Buy
1,389,840
+15,378
+1% +$117K 0.41% 85
2018
Q1 		$10.3M Sell
1,374,462
-7,945
-0.6% -$52.8K 0.4% 91
2017
Q4 		$8.22M Buy
1,382,407
+67,464
+5% +$410K 0.32% 97
2017
Q3 		$9.68M Sell
1,314,943
-49,936
-4% -$317K 0.43% 91
2017
Q2 		$9.27M Buy
1,364,879
+266,763
+24% +$1.97M 0.4% 91
2017
Q1 		$10.4M Sell
1,098,116
-14,702
-1% -$147K 0.51% 82
2016
Q4 		$9.62M Sell
1,112,818
-16,301
-1% -$120K 0.48% 84
2016
Q3 		$7.15M Buy
1,129,119
+164,322
+17% +$993K 0.37% 91
2016
Q2 		$4.07M Buy
964,797
+44,906
+5% +$217K 0.23% 94
2016
Q1 		$4.01M Buy
919,891
+28,219
+3% +$126K 0.23% 96
2015
Q4 		$5.47M Buy
891,672
+409,618
+85% +$2.69M 0.31% 87
2015
Q3 		$2.76M Buy
482,054
+421,104
+691% +$3.23M 0.18% 127
2015
Q2 		$455K Buy
60,950
+7,953
+15% +$48.1K 0.03% 272
2015
Q1 		$317K Buy
52,997
+27,633
+109% +$174K 0.02% 294
2014
Q4 		$192K Buy
+25,364
New +$152K 0.01% 299

Other funds holding PGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Rice Hall James & Associates's PGNX Position: Q4 2019 in Review

Rice Hall James & Associates sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 1,776,490 shares — an estimated $8.98M sold.

Rice Hall James & Associates first reported a position in PGNX in Q4 2014 and held it in 20 quarters. The position peaked at $13.8M in Q2 2019. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • Rice Hall James & Associates reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • Rice Hall James & Associates sold 1,776,490 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $8.98M.
  • Rice Hall James & Associates first reported a position in Progenics Pharmaceuticals Inc in Q4 2014 and held it in 20 quarters.
  • Rice Hall James & Associates's Progenics Pharmaceuticals Inc position peaked at $13.8M in Q2 2019.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Rice Hall James & Associates's 13F filing for Q4 2019, filed 29 Jan 2020.